Pharma RSS Digest - 2026-06-08

Overview

The 48-hour window was light but concentrated around two distinct clinical catalysts—one in oncology cell therapy and one in dermatology—delivered via wire services. OriCell's GPC3 CAR-T became the first of its kind globally to enter a confirmatory Phase II trial for liver cancer, a notable milestone for solid-tumor cell therapy. Dayspring Pharma's CG2001 for androgenetic alopecia met its primary endpoint in Phase II, suggesting a potential new topical combination for a large underserved population. The ADA 2026 Scientific Sessions in New Orleans provided a secondary flow of data, with Novo Nordisk's CagriSema Phase III results and Abbott's diabetic ketoacidosis epidemiology findings rounding out the period.

Key Developments

OriCell's GPC3 CAR-T Clears NMPA Confirmatory Trial in Late-Line Liver Cancer

OriCell's GPC3 CAR-T fda approval update

OriCell Therapeutics announced on June 7, 2026, that China's National Medical Products Administration cleared Ori-C101 to proceed into a confirmatory Phase II trial for GPC3-positive advanced hepatocellular carcinoma, making it the first GPC3-directed immune cell therapy globally to reach this stage and the first CAR-T product for liver cancer to enter a randomized Phase II registration study. The Phase I BEACON data showed a 50% overall objective response rate, 66.7% at the recommended Phase II dose, and a median overall survival of 21.4 months—more than double the approximately 10.6-month historical benchmark for second-line agents—with manageable safety and no immune effector cell-associated neurotoxicity syndrome observed. The therapy demonstrated that 89% of responders achieved objective response by their first post-infusion assessment, with one patient progressing to complete response by month four and remaining in remission at 24 months. The trial will enroll patients who have failed two or more prior lines including both tyrosine kinase inhibitors and immune checkpoint inhibitors, addressing an acute unmet need in a disease where essentially no approved late-line options exist beyond sorafenib-era agents. GPC3 is overexpressed in over 70% of HCC cases and across several other solid tumor types, providing a scientific basis for potential future indication expansion into gastric cancer, lung squamous cell carcinoma, and ovarian clear cell carcinoma. What to watch next is whether Phase II efficacy replicates Phase I results in the larger randomized setting, and how quickly the company can advance toward a biologics license application.

Dayspring Pharma clinical trial update Dayspring Pharma's CG2001 Meets Phase II Endpoint in Androgenetic Alopecia

Dayspring Pharma disclosed positive topline data on June 7, 2026, from a Phase II randomized, double-blind, placebo-controlled trial of CG2001, a topical foam combining 5% minoxidil with 0.075% finasteride, at the 14th World Congress for Hair Research in Seoul. The twice-daily arm achieved a statistically significant increase in target-area hair count of +28.17 hairs/cm² versus +7.68 hairs/cm² for placebo at Week 24, meeting the primary endpoint with a p-value of 0.006, while secondary observations showed sustained hair count gains across earlier timepoints and a trend toward improved subject self-assessments. The therapy was generally well-tolerated with all adverse events mild-to-moderate and no sex-related adverse events reported, addressing a key limitation of oral finasteride by aiming to minimize systemic drug exposure through optimized local follicular delivery. This represents a potential new topical combination therapy for male pattern hair loss, a large underserved market where existing options often involve separate oral and topical regimens with varying adherence. The company has begun engaging with regulatory authorities to outline the next phase of clinical development, suggesting a clear path toward Phase III and eventual filing. What to watch next is the design and timeline for Phase III, regulatory feedback on the development pathway, and whether the safety profile holds in longer-term follow-up given that the 24-week data represents an early snapshot.

Watchlist

• Novo Nordisk's CagriSema Phase III Results (ADA 2026): The amylin-GLP-1 combination therapy demonstrated significant HbA1c reduction of -1.8% and bodyweight reduction of -13.8% in the REIMAGINE 1 trial, with all three Phase III studies meeting their primary endpoints; if approved, it would be the first amylin-GLP-1 combination therapy for type 2 diabetes, offering a new mechanism of action and potentially competing with existing GLP-1 monotherapies. [link]
• Abbott DKA Data and Libre Duo Submission: Abbott presented data showing DKA hospitalizations among people with Type 1 diabetes rose approximately 24% from 2017 to 2024, with nearly 60% of pediatric diabetes hospitalizations now associated with DKA and costs reaching up to $38,000 per stay; the company received CE Mark in May 2026 for its dual glucose-ketone sensing system and has filed for FDA approval, potentially addressing a gap in continuous glucose monitoring where ketones cannot be detected and DKA can develop despite stable-appearing glucose levels. [link]